Affluent Medical achieves major progress in 2024

In 2024, Affluent Medical made significant progress in its clinical and strategic projects. A pivotal agreement with Edwards Lifesciences resulted in an initial payment of €15 million, recognizing its innovation in structural cardiology. In the United States, the FDA approved a fast-track strategy for Kalios™, facilitating its market access.

The development of Epygon, a biomimetic cardiac mitral valve, has intensified in Europe with the opening of new centers. Meanwhile, Artus, an innovative urinary sphincter, has completed its pilot phase in humans, with a view to a pivotal phase in 2025.

Financially, the company has strengthened its structure with an extended horizon until summer 2025. Affluent Medical is thus well positioned to move towards the commercialization of its devices.